Physician profile
Mark E Brewster
NPI 1275773046
$3,638.10
in general payments reported to CMS, 2019-2025
24 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,443 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.11 |
| Education | $257.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.16 | 2024-2025 | |
| Janssen Biotech, INC. | $834.15 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $428.58 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.40 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $182.98 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $135.30 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $133.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $125.51 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $124.10 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $115.35 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $101.05 | 2024-2025 | |
| Integra Lifesciences Corporation | $86.35 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Regeneron Healthcare Solutions, INC. | $60.53 | 2024-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $35.74 | 2025 | |
| Solventum Corporation | $28.82 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22.52 | 2024 | Terlivaz |
| Ferring Pharmaceuticals INC. | $21.04 | 2024 | Rebyota |
| Organon LLC | $20.63 | 2024 | |
| Organogenesis INC. | $17.01 | 2025 | Puraply Wound Matrix |
| Ortho Organizers, INC. | $16.42 | 2025 | Carriere |
| Becton, Dickinson and Company | $15.82 | 2024 | Arista Ah Flexitip |
| Sandoz INC. | $15.06 | 2024 | Hyrimoz |
| Celgene Corporation | $14.63 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $13.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brewster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.